Catherine Coombs, MD, MS, introduces the case of a patient with relapsed/refractory CLL and shares her impressions on the patient’s initial presentation.
A 72-Year-Old Man with R/R Chronic Lymphocytic Leukemia
An expert in treating CLL discusses potential treatment options for a patient with relapsed/refractory CLL who has been previously treated with venetoclax plus obinutuzumab.
Catherine Coombs, MD, MS, reviews factors that impact the selection of treatment in patients with CLL.
A comprehensive review of existing second-line treatment options for patients with R/R CLL.
Catherine Coombs, MD, MS, highlights available data and considerations for retreatment with venetoclax in the relapsed/refractory setting.
A detailed description of emerging treatment options for patients with relapsed/refractory CLL.
Catherine Coombs, MD, MS, shares her thoughts on the future of treatment and where the field is moving for patients with CLL.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
